# An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

> **NCT05594147** · — · COMPLETED · sponsor: **Bayer** · enrollment: 4103 (actual)

## Conditions studied

- Malignant Solid Tumors
- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Non-TKIs
- **DRUG:** Other TKIs
- **DRUG:** Regorafenib (Stivarga, BAY73- 4506)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT05594147
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-31
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 4103 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594147, "An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05594147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*